RLAY (relaytx.com) Enterprise Value-to-Revenue Coefficient

Official company branding of Relay Therapeutics Inc (RLAY)

The enterprise value-to-revenue ratio visualizes the dynamics of the asset managed by a team of experts in structural biology and machine learning. The future market power of Relay Therapeutics (RLAY) is based on the efficacy of innovative oncology drugs. The current operating cash flow deficit is offset by existing capital reserves. The value of 260275.36 is the current figure for this fundamental metric.

relaytx.com (RLAY): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Relay Therapeutics, Inc. (RLAY)

- business market valuation indicators:
Fundamental company valuation:Relay Therapeutics RLAY
Product sample of relaytx.com

This metric compares the total enterprise value of the business with sales volume, excluding the impact of debt load. It determines the market revaluation of operating flows amid high borrowing costs. For Relay Therapeutics (RLAY), this parameter reflects the value of intellectual developments in oncology prior to therapy commercialization. Efficiency of access to capital directly influences the dynamics of the EV/Sales ratio. This chart allows for an assessment of the balance between fundamental biotech risks and capitalization.